Pharma lobby pledges to launch drugs on EU markets no later than two years after approval

European regional differences are too large in regard to the time it takes for drugs to reach individual EU countries post approval, says European lobby organization EFPIA, which is launching a new initiative to reduce inequalities in the area.

Photo: Rob Acket/EMA

On Monday, the European Federation of Pharmaceutical Industries and Associations (EFPIA), which represents pharmaceutical firms across Europe, has made a pledge to ”reduce inequalities in patient access to medicines across Europe,” the organization has announced in a press release, as reported by Endpoints News.

The proposal entails the commitment by member companies to file for market access, including pricing and reimbursement, in all EU member countries ”as soon as possible and no later than two years” post EU approval, should local authorities enable it.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Rumored GN purchase unlikely but not impossible, say analysts

A low value assessment, a high structural value, and no dominant shareholders make GN Group a reasonable investment case for international private equity firms and industrial players. But just how likely is it? Analysts reveal their best bets for what a GN acquisition could look like.

New CFO wants to shake things up at WSA

A mere month into her new job, Marianne Wiinholt, WS Audiology’s fifth chief financial officer since the firm was established through a merger in 2019, is heralding great structural changes.

Further reading

Related articles

Latest news

See all jobs